Who buys BIOLASE stock?
BIOL stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, and Acadian Asset Management LLC. View insider buying and selling activity for BIOLASE or or view top insider-buying stocks.
What does BIOLASE do?
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals.
How do you forecast BIOLASE stock performance?
We forecast BIOLASE stock performance using neural networks based on historical data on BIOLASE stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
What are analysts'price targets for BIOLASE's stock?
4 analysts have issued 1-year price targets for BIOLASE's stock. Their forecasts range from $2.00 to $3.00. On average, they expect BIOLASE's stock price to reach $2.50 in the next year.
Is Biolase stock worth buying?
The 4 analysts offering 12-month price forecasts for BIOLASE Inc have a median target of 18.50, with a high estimate of 75.00 and a low estimate of 10.00. The median estimate represents a +283.82% increase from the last price of 4.82.
Will biolase be delisted?
Nasdaq has told BIOLASE that it has until May 23, 2022 to get its share price above $1 and keep it there for a minimum of 10 consecutive trading days. If it can do that, it will regain compliance with the exchange and avoid being delisted.
Who owns Biolase stock?
Top 10 Owners of BIOLASE IncStockholderStakeShares ownedZhang Financial LLC44.06%2,720HRT Financial LLC33.93%2,095Orion Capital Management LLC (CA)32.39%2,000Renaissance Technologies LLC24.68%1,5246 more rows
What does Biol company do?
BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products.
Is Biol doing a reverse split?
Biolase announces reverse stock split Accordingly, the board of directors made a decision to effect a 1-for-25 reverse stock split effective 11:59 p.m. EST on April 28, 2022. It will reduce the company's outstanding shares of common stock to ~6.2 million from ~154 million.
Who owns Biol?
The company's largest shareholder is Armistice Capital LLC, with ownership of 6.5%. Schuler Family Foundation, Endowment Arm is the second largest shareholder owning 5.6% of common stock, and Oracle Investment Management, Inc.
Why did BIOLASE stock go up?
BIOLASE MAINTAINS GROWTH MOMENTUM AS FIRST QUARTER REVENUE INCREASED 25% YEAR OVER YEAR. BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31, 2022.
What is a reverse split on stocks?
When a company completes a reverse stock split, each outstanding share of the company is converted into a fraction of a share. For example, if a company declares a one for ten reverse stock split, every ten shares that you own will be converted into a single share.
What is a BIOLASE dentist?
BIOLASE is the world's leading innovator in dental lasers. With thousands of lasers in use in operatories worldwide, millions of patients have experienced the benefits of laser dentistry, such as less aerosols, gentler procedures and comfortable healing. Dental Professionals.
Is BIOLASE a buy right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 2 buy rati...
How has BIOLASE's stock price been impacted by COVID-19?
BIOLASE's stock was trading at $0.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since th...
Are investors shorting BIOLASE?
BIOLASE saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 4,440,000 shares, a de...
When is BIOLASE's next earnings date?
BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022. View our earnings forecast for BIOLASE .
How can I listen to BIOLASE's earnings call?
BIOLASE will be holding an earnings conference call on Thursday, March 17th at 4:30 PM Eastern. Interested parties can register for or listen to th...
How were BIOLASE's earnings last quarter?
BIOLASE, Inc. (NASDAQ:BIOL) issued its quarterly earnings data on Wednesday, November, 10th. The medical technology company reported ($0.02) EPS fo...
When did BIOLASE's stock split? How did BIOLASE's stock split work?
Shares of BIOLASE reverse split on the morning of Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number...
What guidance has BIOLASE issued on next quarter's earnings?
BIOLASE issued an update on its fourth quarter 2021 earnings guidance on Monday, February, 7th. The company provided earnings per share (EPS) guida...
What price target have analysts set for BIOL?
2 brokers have issued 12-month price objectives for BIOLASE's stock. Their forecasts range from $2.00 to $3.00. On average, they expect BIOLASE's s...
About BIOLASE
BIOLASE (NASDAQ:BIOL) Frequently Asked Questions
BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products.
Recently Viewed Tickers
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOLASE stock. View analyst ratings for BIOLASE or view top-rated stocks.
Biolase Inc
Visit a quote page and your recently viewed tickers will be displayed here.
Historical and forecast chart of BIOLASE stock
BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products.
BIOLASE Daily Price Targets
The chart below shows the historical price of BIOLASE stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the BIOLASE stock price can be found in the table below.
BIOLASE forecast for this year
Forecast target price for 02-23-2022: $ 0.40. Positive dynamics for BIOLASE shares will prevail with possible volatility of 4.000%.
BIOLASE information and performance
An uptrend is forecast for this month with an optimal target price of $ 0.44928. Pessimistic: $0.43. Optimistic: $0.47
BIOLASE (BIOL) stock dividend
BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products.
Biolase Technology stock news
BIOLASE last paid dividends on 06/24/2005. The next scheduled payment will be on 05/11/2018. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data.
Why Biolase Technology stock got a boost
Recently, Biolase struck a strategic partnership with Einstein Healthcare Network, which is a leading nonprofit healthcare system. The arrangement, focused on endodontist training, promises to bring more customers to Biolase and fuel its revenue growth.
BOIL stock price forecast
Biolase stock shot up 34 percent on April 8 and closed above $1. The stock retreated about 4 percent to $0.98 in the pre-market session on April 9. It seems some investors moved to take profits after the previous day’s rally drove Biolase’s gains in the past year to 325 percent.
Biolase Technology (BIOL) stock looks like a good investment
The recent spike has left investors curious about Biolase's stock price forecast. Will it come down soon or keep rising and exit the penny stock zone? BOIL's stock outlook leans bullish right now. The consensus target price of $1.94 implies a 90 percent upside from the current level. The high target price of $2 implies a 100 percent upside.
Biolase (BIOL)
There are several reasons you might want to buy BIOL stock now. The 30 percent pullback from the peak has opened a window to enter the stock at a discount. Also, Biolase continues to enter partnership arrangements that have the potential to unlock long-term sales growth.
Biolase, Inc. - Hold
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
The Worldwide Leader in Dental Lasers
Zacks' proprietary data indicates that Biolase, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the BIOL shares relative to the market in the next few months. In addition, Biolase, Inc.
World Class Training, Service and Support
BIOLASE is the world’s leading innovator in dental lasers. With thousands of lasers in use in operatories worldwide, millions of patients have experienced the benefits of laser dentistry, such as less aerosols, gentler procedures and comfortable healing.
Nasdaq Capital Market (Nasdaq)
We take pride in helping our owners sucessfully integrate laser technology into their practice with award-winning training, service and online support resources.
Environmental, Social, and Governance Rating
A medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
